Wegovy® is an unfunded prescription medicine - patient co-payment for medicine and healthcare professional fees apply.

Wegovy® FlexTouch® (semaglutide solution for injection) is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 to <30 kg/m2 (overweight) in the presence of ≥1 weight-related comorbidity; in adolescents ≥12 years with initial obesity* and body weight >60 kg (*obesity (BMI ≥95th percentile) as defined on sex- and age-specific BMI growth charts (CDC.gov) – refer to full datasheet); as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease, BMI ≥27 kg/m2, and without established Type 1 or Type 2 diabetes. Before prescribing please  review Wegovy® Data Sheet for information on indication, dosage, contraindications, precautions, interactions and adverse events available from https://www.medsafe. govt.nz/Profs/Datasheet/w/wegovyinjection.pdf or https://www.novonordisk.co.nz/our-products/our-products.html